美國前列腺癌生物標記市場規模、佔有率和趨勢分析報告：按類型、應用、最終用途和細分市場預測，2025-2033 年

市場規模和趨勢

預計 2024 年美國前列腺癌生物標記市場價值將達到 17 億美元，預計 2025 年至 2033 年期間的複合年成長率為 14.74%。

前列腺癌盛行率的上升、早期檢測意識的增強以及精準診斷技術的普及推動了市場的成長。液態切片、基因組學和非侵入性生物標記技術的進步正在提高篩檢的準確性和患者分層。此外，個人化治療方案的需求不斷成長，以及PSA、PCA3和基因表現檢測（例如Decipher和Oncotype DX）的優惠報銷框架，也進一步推動了市場的成長。策略夥伴關係和持續的研發投入也正在擴大生物標記的產品線和商業性應用。

前列腺癌是美國男性最常見的惡性腫瘤之一。根據美國癌症協會的數據，八分之一的男性在其一生中會被診斷出患有這種疾病。僅在 2022 年，就將報告約 268,500 例新患者，導致約 34,500 人死亡，使其成為美國男性癌症死亡的第二大原因。目前，美國有超過 310 萬名男性罹患攝護腺癌。如此高的盛行率，加上 PSA 檢測等傳統診斷方法的局限性，缺乏區分良性和惡性疾病的特異性，因此對能夠早期發現、風險分層和個性化治療的新型生物標記的需求強烈。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國前列腺癌生物標記市場變數、趨勢和範圍

• 美國前列腺癌生物標記市場的系統展望
  • 母市場展望
• 滲透和成長前景圖
• 管道分析
  • 篩檢和早期檢測
  • 診斷和風險分層
  • 預後和治療監測
  • 伴隨診斷
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
• 前列腺癌生物標記：市場分析工具
  • 產業分析—波特五力分析
  • PESTLE分析

第4章美國前列腺癌生物標記市場：細分分析（按類型），2021-2033 年

• 美國前列腺癌生物標記市場：類型變異分析

第5章美國前列腺癌生物標記市場：細分分析、應用、2021-2033

• 美國前列腺癌生物標記市場：應用差異分析

第6章美國前列腺癌生物標記市場：細分分析（按最終用途），2021-2033 年

• 美國前列腺癌生物標記市場：最終用途變異分析

第7章美國前列腺癌生物標記市場：競爭分析

• 公司分類
• 戰略地圖
  • 新產品發布
  • 夥伴關係
  • 獲得
  • 合作
  • 資金籌措
• 2022年企業市場佔有率分析
• 公司簡介
  • Exact Sciences Corporation
  • Myriad Genetics, Inc.
  • Bio-techne
  • Exodx
  • Opko Health, Inc.
  • Mdxhealth
  • Veracyte, Inc.
  • Beckman Coulter, Inc.
  • Nucleix
  • Diacarta

Market Size & Trends:

The U.S. prostate cancer biomarkers market size was estimated at USD 1.7 billion in 2024 and is expected to grow at a CAGR of 14.74% from 2025 to 2033. The market growth is driven by the rising prevalence of prostate cancer, awareness around early detection, and adoption of precision diagnostics. Advancements in liquid biopsy, genomics, and non-invasive biomarker technologies are enhancing screening accuracy and patient stratification. Additionally, the rising demand for personalized treatment planning, along with favorable reimbursement frameworks for diagnostic tests such as PSA, PCA3, and gene-expression panels (e.g., Decipher, Oncotype DX), is further accelerating market growth. Strategic collaborations and continuous R&D investment are also expanding the biomarker pipeline and commercial availability.

Prostate cancer is one of the most prevalent malignancies affecting men in the United States. According to the American Cancer Society, 1 in 8 men will be diagnosed with the disease in their lifetime. In 2022 alone, an estimated 268,500 new cases were reported, with approximately 34,500 deaths, making it the second leading cause of cancer death among American men. Today, over 3.1 million men in the U.S. are living with prostate cancer. This substantial patient population, along with limitations in traditional diagnostics such as PSA testing, which lacks specificity to distinguish between benign and malignant conditions, has created strong demand for novel biomarkers that can enable earlier detection, improved risk stratification, and treatment personalization.

U.S. Prostate Cancer Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-markets from 2021 to 2033. For this study, Grand View Research has segmented the U.S. prostate cancer biomarkers market report based on type, application, and end-use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic Biomarkers
  • Protein Biomarkers
  • Cell-based Biomarkers
  • Metabolomic Biomarkers
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Screening and Early Detection
  • Diagnosis and Risk Stratification
  • Prognosis and Treatment Monitoring
  • Companion Diagnostics
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Diagnostic Laboratories
  • Academic and Research Institutes
  • Biopharmaceutical Companies

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definition
    • 1.1.1.1 Application Segment
    • 1.1.1.2 Type Segment
    • 1.1.1.3 End USE Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 GVR's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Application And Type Snapshot
• 2.3 End USE Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 U.S. Prostate Cancer Biomarkers Market Variables, Trends, And Scope

• 3.1 U.S. Prostate Cancer Biomarkers Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Pipeline Analysis
  • 3.3.1 Screening And Early Detection
  • 3.3.2 Diagnosis And Risk Stratification
  • 3.3.3 Prognosis And Treatment Monitoring
  • 3.3.4 Companion Diagnostics
• 3.4 Market Dynamics
  • 3.4.1 Market Driver Analysis
    • 3.4.1.1 Rising Prevalence Of Prostate Cancer
    • 3.4.1.2 Advancements In Genomic And Proteomic Technologies
    • 3.4.1.3 Supportive Government And Research Initiatives
  • 3.4.2 Market Restraint Analysis
    • 3.4.2.1 High Cost Of Biomarker-based Tests
    • 3.4.2.2 Uneven Access To Advanced Diagnostic Infrastructure
• 3.5 Prostate Cancer Biomarkers: Market Analysis Tools
  • 3.5.1 Industry Analysis - Porter's
  • 3.5.2 Pestle Analysis

Chapter 4 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By Type, 2021 - 2033 (USD Million)

• 4.1 U.S. Prostate Cancer Biomarkers Market: Type Movement Analysis
  • 4.1.1 Genetic Biomarkers
    • 4.1.1.1 Genetic Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.2 Protein Biomarkers
    • 4.1.2.1 Protein Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.3 Cell-based Biomarkers
    • 4.1.3.1 Cell-based Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)
  • 4.1.5 Metabolomic Biomarkers
    • 4.1.5.1 Metabolomic Biomarkers U.S. Prostate Cancer Biomarkers Market, 2021 - 2033 (USD Million)

Chapter 5 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By Application, 2021 - 2033 (USD Million)

• 5.1 U.S. Prostate Cancer Biomarkers Market: Application Movement Analysis
  • 5.1.1 Screening And Early Detection
    • 5.1.1.1 Screening And Early Detection Market, 2021 - 2033 (USD Million)
  • 5.1.2 Diagnosis And Risk Stratification
  • 515.2.1 Diagnosis And Risk Stratification Market, 2021 - 2033 (USD Million)
  • 5.1.3 Prognosis And Treatment Monitoring
  • 51.3.1 Prognosis And Treatment Monitoring Market, 2021 - 2033 (USD Million)
  • 5.1.4 Companion Diagnostics
    • 5.1.4.1 Companion Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 6 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By End USE, 2021 - 2033 (USD Million)

• 6.1 U.S. Prostate Cancer Biomarkers Market: End USE Movement Analysis
  • 6.1.1 Hospitals And Diagnostic Laboratories
    • 6.1.1.1 Hospitals And Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
  • 6.1.2 Academic And Research Institutes
    • 6.1.2.1 Academic And Research Institutes Market, 2021 - 2033 (USD Million)
  • 6.1.3 Biopharmaceutical Companies
    • 6.1.3.1 Biopharmaceutical Companies Market, 2021 - 2033 (USD Million)

Chapter 7 U.S. Prostate Cancer Biomarkers Market: Competitive Analysis

• 7.1 Company Categorization
• 7.2 Strategy Mapping
  • 7.2.1 New Product Launch
  • 7.2.2 Partnerships
  • 7.2.3 Acquisition
  • 7.2.4 Collaboration
  • 7.2.5 Funding
• 7.3 Company Market Share Analysis, 2022
• 7.4 Company Profiles
  • 7.4.1 Exact Sciences Corporation
    • 7.4.1.1 Company Overview
    • 7.4.1.2 Financial Performance
    • 7.4.1.3 Product Benchmarking
    • 7.4.1.4 Strategic Initiatives
  • 7.4.2 Myriad Genetics, Inc.
    • 7.4.2.1 Company Overview
    • 7.4.2.2 Financial Performance
    • 7.4.2.3 Product Benchmarking
    • 7.4.2.4 Strategic Initiatives
  • 7.4.3 Bio-techne
    • 7.4.3.1 Company Overview
    • 7.4.3.2 Financial Performance
    • 7.4.3.3 Product Benchmarking
    • 7.4.3.4 Strategic Initiatives
  • 7.4.4 Exodx
    • 7.4.4.1 Company Overview
    • 7.4.4.2 Product Benchmarking
  • 7.4.5 Opko Health, Inc.
    • 7.4.5.1 Company Overview
    • 7.4.5.2 Product Benchmarking
    • 7.4.5.3 Strategic Initiatives
  • 7.4.6 Mdxhealth
    • 7.4.6.1 Company Overview
    • 7.4.6.2 Financial Performance
    • 7.4.6.3 Product Benchmarking
    • 7.4.6.4 Strategic Initiatives
  • 7.4.7 Veracyte, Inc.
    • 7.4.7.1 Company Overview
    • 7.4.7.2 Financial Performance
    • 7.4.7.3 Product Benchmarking
    • 7.4.7.4 Strategic Initiatives
  • 7.4.8 Beckman Coulter, Inc.
    • 7.4.8.1 Company Overview
    • 7.4.8.2 Product Benchmarking
  • 7.4.9 Nucleix
    • 7.4.9.1 Company Overview
    • 7.4.9.2 Financial Performance
    • 7.4.9.3 Product Benchmarking
    • 7.4.9.4 Strategic Initiatives
  • 7.4.10 Diacarta
    • 7.4.10.1 Company Overview
    • 7.4.10.2 Product Benchmarking
    • 7.4.10.3 Strategic Initiatives

List of Tables

• Table 1 List of Abbreviations
• Table 2 U.S. prostate cancer biomarkers market, by application, 2021 - 2033 (USD Million)
• Table 3 U.S. prostate cancer biomarkers market, by type, 2021 - 2033 (USD Million)
• Table 4 U.S. prostate cancer biomarkers market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Prostate Cancer Biomarkers market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (Type and application)
• Fig. 11 Segment snapshot (End use)
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Biomarkers market value, 2024 (USD Million)
• Fig. 14 Prostate Cancer Biomarkers market dynamics
• Fig. 15 Prevalence of Screening and Early Detection by age group, 2024
• Fig. 16 Prostate Cancer Biomarkers market: PORTER's analysis
• Fig. 17 Prostate Cancer Biomarkers market: PESTLE analysis
• Fig. 18 Prostate Cancer Biomarkers market: Type outlook and key takeaways
• Fig. 19 Prostate Cancer Biomarkers market: Type movement analysis
• Fig. 20 Genetic Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 21 Protein Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 22 Cell-based Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 23 Metabolomic Biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 24 Prostate Cancer Biomarkers market: Application outlook and key takeaways
• Fig. 25 Prostate Cancer Biomarkers market: Application movement analysis
• Fig. 26 Screening and Early Detection market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 27 Diagnosis and Risk Stratification market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 28 Prognosis and Treatment Monitoring market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 29 Companion Diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 30 Prostate Cancer Biomarkers market: End use outlook and key takeaways
• Fig. 31 Prostate Cancer Biomarkers market: End use movement analysis
• Fig. 32 Hospitals and Diagnostic Laboratories market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 33 Academic and Research Institutes market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 34 Biopharmaceutical Companies market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 35 Key company categorization
• Fig. 36 Company market positioning
• Fig. 37 Company market share analysis, 2024
• Fig. 38 Strategic framework